Last reviewed · How we verify
ALXN1820 SC — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
ALXN1820 SC (ALXN1820 SC) — Alexion Pharmaceuticals, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ALXN1820 SC TARGET | ALXN1820 SC | Alexion Pharmaceuticals, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ALXN1820 SC CI watch — RSS
- ALXN1820 SC CI watch — Atom
- ALXN1820 SC CI watch — JSON
- ALXN1820 SC alone — RSS
Cite this brief
Drug Landscape (2026). ALXN1820 SC — Competitive Intelligence Brief. https://druglandscape.com/ci/alxn1820-sc. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab